- Home
- IAE vs CASI Comparison
IAE vs CASI Comparison
Compare IAE & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAE
- CASI
- Stock Information
- Founded
- IAE 2007
- CASI 1991
- Country
- IAE United States
- CASI China
- Employees
- IAE N/A
- CASI N/A
- Industry
- IAE Trusts Except Educational Religious and Charitable
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- IAE Finance
- CASI Health Care
- Exchange
- IAE Nasdaq
- CASI Nasdaq
- Market Cap
- IAE 67.9M
- CASI 58.8M
- IPO Year
- IAE N/A
- CASI 1996
- Fundamental
- Price
- IAE $6.16
- CASI $2.99
- Analyst Decision
- IAE
- CASI Strong Buy
- Analyst Count
- IAE 0
- CASI 1
- Target Price
- IAE N/A
- CASI $6.00
- AVG Volume (30 Days)
- IAE 46.3K
- CASI 54.4K
- Earning Date
- IAE 01-01-0001
- CASI 11-15-2024
- Dividend Yield
- IAE 10.21%
- CASI N/A
- EPS Growth
- IAE N/A
- CASI N/A
- EPS
- IAE N/A
- CASI N/A
- Revenue
- IAE N/A
- CASI $22,055,000.00
- Revenue This Year
- IAE N/A
- CASI N/A
- Revenue Next Year
- IAE N/A
- CASI $134.79
- P/E Ratio
- IAE N/A
- CASI N/A
- Revenue Growth
- IAE N/A
- CASI N/A
- 52 Week Low
- IAE $5.31
- CASI $2.05
- 52 Week High
- IAE $6.45
- CASI $8.19
- Technical
- Relative Strength Index (RSI)
- IAE 41.66
- CASI 34.42
- Support Level
- IAE $6.10
- CASI $2.86
- Resistance Level
- IAE $6.33
- CASI $3.47
- Average True Range (ATR)
- IAE 0.05
- CASI 0.48
- MACD
- IAE 0.00
- CASI -0.00
- Stochastic Oscillator
- IAE 26.09
- CASI 28.21
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.